MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
217.81
-0.25
-0.11%
After Hours: 218.37 +0.56 +0.26% 18:15 05/24 EDT
OPEN
218.21
PREV CLOSE
218.06
HIGH
219.44
LOW
217.06
VOLUME
770.94K
TURNOVER
0
52 WEEK HIGH
319.76
52 WEEK LOW
189.44
MARKET CAP
31.71B
P/E (TTM)
27.21
1D
5D
1M
3M
1Y
5Y
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
NASDAQ · 2d ago
Biogen’s Strategic Diversification and Financial Strategy Garner Outperform Rating
TipRanks · 2d ago
Strategic Acquisitions and Clinical Catalysts Bolster Biogen’s Buy Rating
TipRanks · 2d ago
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
A class action lawsuit has been filed against Biogen Inc. Investors have until July 22, 2024 to apply to be appointed as a lead plaintiff in the lawsuit. The lawsuit alleges that Biogen made false and/or misleading statements. Biogen's stock price has declined in recent months.
Barchart · 2d ago
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC, notifies investors that a class action lawsuit has been filed against Biogen Inc. The lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws. Investors are encouraged to join this case.
Barchart · 2d ago
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
NASDAQ · 3d ago
Nasdaq 100 Movers: GFS, NVDA
NASDAQ · 3d ago
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
NASDAQ · 3d ago
More
About BIIB
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.